[The influence of alpha-dihydroergocryptine derivatives on psychomotor manifestations in Parkinson disease].
The paper presents the results of administration of alpha-dihydroergocryptine preparation (vasobral) to parkinsonic patients. It was prescribed to 20 patients with parkinsonism together with the specific therapy. Clinical state as well as the level of anxiety and depression was estimated using standard scales both before and after treatment. A high efficiency of vasobral was found as regards such symptoms as disorders of memory, headache, vertigo, a noise in ears and head, asthenic state. In some patients functional activity increased, in 4 patients a dose of dopaminergic preparations was successfully decreased by 25%. An important aspect of vasobral activity was also a decrease of anxious-depressive symptoms. A conclusion was made about efficiency of vasobral in combined treatment of parkinsonic patients.
Sadekov
R A
RA
D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002110:Caffeine / Q000494:pharmacology* / Q000627:therapeutic use*; D004088:Dihydroergotoxine / Q000494:pharmacology* / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011597:Psychomotor Performance / Q000187:drug effects*; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D004338:Drug Combinations; D004088:Dihydroergotoxine; D002110:Caffeine; C055581:Vasobral
Vliianie proizvodnogo al'fa-digidroérgokriptina na psikhicheskie i dvigatel'nye proiavleniia parkinsonizma.